DigestRedComo funciona
Red
/
Empresas
Au
No verificado

Aulos Bioscience

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

11 Comunicados de prensa

Ver todos los comunicados de prensa
07/11/2025
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
New Phase 2 Data for Aulos Bioscience’s Imneskibart Reveal Clinical Activity in Melanoma and Non-Small Cell Lung Cancer
Fuente
Aulos Bioscience
Editor
Business Wire
1.00
0
03/10/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Industria
Aulos Bioscience to Present Updated Phase 2 Data for Imneskibart (AU-007) in Melanoma and Non-Small Cell Lung Cancer at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Fuente
Aulos Bioscience
Editor
Business Wire
1.00
0
29/04/2025
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Aulos Bioscience Presents New Phase 2 Data for AU-007 Demonstrating Continued Strong Anti-Tumor Activity in Advanced Cancers at AACR Annual Meeting
Fuente
Aulos Bioscience
Editor
Business Wire
1.00
0
14/04/2025
Industria
Oncología
Salud
Técnica
Medicina - Varios
Farmacéutica
Biotecnología
Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of Melanoma
Fuente
Aulos Bioscience
Editor
Business Wire
1.00
0
25/03/2025
Eventos
Ciencia
Técnica
Medicina - Varios
Biotecnología
Farmacéutica
Salud
Oncología
Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting
Fuente
Aulos Bioscience
Editor
Business Wire
1.00
0
27/11/2024
Industria
Oncología
Salud
Técnica
Medicina - Varios
Farmacéutica
Biotecnología
Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating the Combination of Avelumab and AU-007 for the Treatment of Non-Small Cell Lung Cancer
Fuente
Aulos Bioscience
Editor
Business Wire
1.00
0
07/11/2024
Eventos
Industria
Técnica
Ciencia
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Oncología
Strong Evidence of AU-007’s Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Fuente
Aulos Bioscience
Editor
Business Wire
1.00
0
07/11/2024
Eventos
Industria
Técnica
Ciencia
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Oncología
SITC: Aulos Bioscience Presents Strong Evidence of AU-007’s Anti-Tumor Activity
Fuente
Aulos Bioscience
Editor
Business Wire
1.00
0
23/10/2024
Eventos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Aulos Bioscience Presents Phase 2 Dose Selection Data for Novel IL-2 Therapeutic Antibody, AU-007, at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Fuente
Aulos Bioscience
Editor
Business Wire
1.00
0
09/10/2024
Eventos
Ferias y Congresos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Aulos Bioscience Announces Presentation Detailing Phase 2 Dose Selection for AU-007 in Solid Tumor Treatment at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Fuente
Aulos Bioscience
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0